Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone
Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions. Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups...
Gespeichert in:
| Veröffentlicht in: | Clinical & experimental ophthalmology 2010-05, Vol.38 (4), p.346-352 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 352 |
|---|---|
| container_issue | 4 |
| container_start_page | 346 |
| container_title | Clinical & experimental ophthalmology |
| container_volume | 38 |
| creator | Hoffart, Louis Matonti, Frederic Conrath, John Daniel, Laurent Ridings, Bernard Masson, Guillaume S Chavane, Frederic |
| description | Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions.
Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer‐assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.
Results: At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively).
Conclusion: Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short‐term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches. |
| doi_str_mv | 10.1111/j.1442-9071.2010.02252.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_787040003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>787040003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4402-c9b0bf52ec54a0f3ceb1e6251e5ff971919e756b764f937166f02310364ead293</originalsourceid><addsrcrecordid>eNqNkcFq3DAQhk1paNK0r1B0Kz3sVpJlaV3oISxJNrA0FFoKvYixPcLa2NZWsje7eZI-buV4u-foomHm-_-B-ZOEMDpn8X3ezJkQfJZTxeacxi7lPOPz_avk4jR4fayloOI8eRvChlKa8VS-Sc45o0rxBb1I_t51tS1sb11HnCGl8x1CQzp0Owjl0IC3T_A8BdOjJ9A8QGNJMfjuS6TbbQTCpK2sMeix60nlAoaxVeAOSvs0tFAQ25HWda6v0cP2QFz0CsGVFnqsyKPta1LhHlrsa4iG-C45M9AEfH_8L5OfN9c_lqvZ-v72bnm1npVCUD4r84IWJuNYZgKoSUssGEqeMcyMyRXLWY4qk4WSwuSpYlIaylNGUykQKp6nl8mnybeGRm-9bcEftAOrV1drPfYivlA5lTsW2Y8Tu_Xuz4Ch160NJTYNxHsNQauFoiJeOY3kYiJL70LwaE7WjOoxQr3RYzp6TEqPEernCPU-Sj8clwxFi9VJ-D-zCHydgEfb4OHFxnp5fT9WUT-b9Db0uD_pwT9oqVKV6V_fbvWNWK8W_LvUv9N_pqW7pQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>787040003</pqid></control><display><type>article</type><title>Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Hoffart, Louis ; Matonti, Frederic ; Conrath, John ; Daniel, Laurent ; Ridings, Bernard ; Masson, Guillaume S ; Chavane, Frederic</creator><creatorcontrib>Hoffart, Louis ; Matonti, Frederic ; Conrath, John ; Daniel, Laurent ; Ridings, Bernard ; Masson, Guillaume S ; Chavane, Frederic</creatorcontrib><description>Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions.
Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer‐assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.
Results: At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively).
Conclusion: Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short‐term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches.</description><identifier>ISSN: 1442-6404</identifier><identifier>ISSN: 2155-9570</identifier><identifier>EISSN: 1442-9071</identifier><identifier>EISSN: 2155-9570</identifier><identifier>DOI: 10.1111/j.1442-9071.2010.02252.x</identifier><identifier>PMID: 21077280</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject><![CDATA[Alkalies - adverse effects ; angiogenesis inhibitor ; Angiogenesis Inhibitors - administration & dosage ; Animals ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Blood Vessels - pathology ; Burns, Chemical - complications ; Burns, Chemical - pathology ; Burns, Chemical - prevention & control ; Cicatrix - etiology ; Conjunctiva ; Cornea - blood supply ; Cornea - pathology ; corneal neovascularization ; Corneal Opacity - etiology ; Dexamethasone - administration & dosage ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Eye Burns - etiology ; Eye Burns - pathology ; Eye Burns - prevention & control ; Glucocorticoids - administration & dosage ; Human health and pathology ; Injections, Intraocular ; Life Sciences ; Male ; Neovascularization, Pathologic - etiology ; Neovascularization, Pathologic - prevention & control ; Rats ; Rats, Inbred BN ; Sensory Organs ; steroids ; Treatment Outcome]]></subject><ispartof>Clinical & experimental ophthalmology, 2010-05, Vol.38 (4), p.346-352</ispartof><rights>2010 The Authors. Journal compilation © 2010 Royal Australian and New Zealand College of Ophthalmologists</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4402-c9b0bf52ec54a0f3ceb1e6251e5ff971919e756b764f937166f02310364ead293</citedby><cites>FETCH-LOGICAL-c4402-c9b0bf52ec54a0f3ceb1e6251e5ff971919e756b764f937166f02310364ead293</cites><orcidid>0000-0001-7916-2640</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-9071.2010.02252.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-9071.2010.02252.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,885,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21077280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02387906$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffart, Louis</creatorcontrib><creatorcontrib>Matonti, Frederic</creatorcontrib><creatorcontrib>Conrath, John</creatorcontrib><creatorcontrib>Daniel, Laurent</creatorcontrib><creatorcontrib>Ridings, Bernard</creatorcontrib><creatorcontrib>Masson, Guillaume S</creatorcontrib><creatorcontrib>Chavane, Frederic</creatorcontrib><title>Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</title><title>Clinical & experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions.
Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer‐assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.
Results: At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively).
Conclusion: Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short‐term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches.</description><subject>Alkalies - adverse effects</subject><subject>angiogenesis inhibitor</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Blood Vessels - pathology</subject><subject>Burns, Chemical - complications</subject><subject>Burns, Chemical - pathology</subject><subject>Burns, Chemical - prevention & control</subject><subject>Cicatrix - etiology</subject><subject>Conjunctiva</subject><subject>Cornea - blood supply</subject><subject>Cornea - pathology</subject><subject>corneal neovascularization</subject><subject>Corneal Opacity - etiology</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Eye Burns - etiology</subject><subject>Eye Burns - pathology</subject><subject>Eye Burns - prevention & control</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Human health and pathology</subject><subject>Injections, Intraocular</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Neovascularization, Pathologic - etiology</subject><subject>Neovascularization, Pathologic - prevention & control</subject><subject>Rats</subject><subject>Rats, Inbred BN</subject><subject>Sensory Organs</subject><subject>steroids</subject><subject>Treatment Outcome</subject><issn>1442-6404</issn><issn>2155-9570</issn><issn>1442-9071</issn><issn>2155-9570</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFq3DAQhk1paNK0r1B0Kz3sVpJlaV3oISxJNrA0FFoKvYixPcLa2NZWsje7eZI-buV4u-foomHm-_-B-ZOEMDpn8X3ezJkQfJZTxeacxi7lPOPz_avk4jR4fayloOI8eRvChlKa8VS-Sc45o0rxBb1I_t51tS1sb11HnCGl8x1CQzp0Owjl0IC3T_A8BdOjJ9A8QGNJMfjuS6TbbQTCpK2sMeix60nlAoaxVeAOSvs0tFAQ25HWda6v0cP2QFz0CsGVFnqsyKPta1LhHlrsa4iG-C45M9AEfH_8L5OfN9c_lqvZ-v72bnm1npVCUD4r84IWJuNYZgKoSUssGEqeMcyMyRXLWY4qk4WSwuSpYlIaylNGUykQKp6nl8mnybeGRm-9bcEftAOrV1drPfYivlA5lTsW2Y8Tu_Xuz4Ch160NJTYNxHsNQauFoiJeOY3kYiJL70LwaE7WjOoxQr3RYzp6TEqPEernCPU-Sj8clwxFi9VJ-D-zCHydgEfb4OHFxnp5fT9WUT-b9Db0uD_pwT9oqVKV6V_fbvWNWK8W_LvUv9N_pqW7pQ</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Hoffart, Louis</creator><creator>Matonti, Frederic</creator><creator>Conrath, John</creator><creator>Daniel, Laurent</creator><creator>Ridings, Bernard</creator><creator>Masson, Guillaume S</creator><creator>Chavane, Frederic</creator><general>Blackwell Publishing Asia</general><general>OMICS Group</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-7916-2640</orcidid></search><sort><creationdate>201005</creationdate><title>Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</title><author>Hoffart, Louis ; Matonti, Frederic ; Conrath, John ; Daniel, Laurent ; Ridings, Bernard ; Masson, Guillaume S ; Chavane, Frederic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4402-c9b0bf52ec54a0f3ceb1e6251e5ff971919e756b764f937166f02310364ead293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Alkalies - adverse effects</topic><topic>angiogenesis inhibitor</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Blood Vessels - pathology</topic><topic>Burns, Chemical - complications</topic><topic>Burns, Chemical - pathology</topic><topic>Burns, Chemical - prevention & control</topic><topic>Cicatrix - etiology</topic><topic>Conjunctiva</topic><topic>Cornea - blood supply</topic><topic>Cornea - pathology</topic><topic>corneal neovascularization</topic><topic>Corneal Opacity - etiology</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Eye Burns - etiology</topic><topic>Eye Burns - pathology</topic><topic>Eye Burns - prevention & control</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Human health and pathology</topic><topic>Injections, Intraocular</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Neovascularization, Pathologic - etiology</topic><topic>Neovascularization, Pathologic - prevention & control</topic><topic>Rats</topic><topic>Rats, Inbred BN</topic><topic>Sensory Organs</topic><topic>steroids</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffart, Louis</creatorcontrib><creatorcontrib>Matonti, Frederic</creatorcontrib><creatorcontrib>Conrath, John</creatorcontrib><creatorcontrib>Daniel, Laurent</creatorcontrib><creatorcontrib>Ridings, Bernard</creatorcontrib><creatorcontrib>Masson, Guillaume S</creatorcontrib><creatorcontrib>Chavane, Frederic</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical & experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffart, Louis</au><au>Matonti, Frederic</au><au>Conrath, John</au><au>Daniel, Laurent</au><au>Ridings, Bernard</au><au>Masson, Guillaume S</au><au>Chavane, Frederic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</atitle><jtitle>Clinical & experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2010-05</date><risdate>2010</risdate><volume>38</volume><issue>4</issue><spage>346</spage><epage>352</epage><pages>346-352</pages><issn>1442-6404</issn><issn>2155-9570</issn><eissn>1442-9071</eissn><eissn>2155-9570</eissn><abstract>Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions.
Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer‐assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.
Results: At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively).
Conclusion: Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short‐term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>21077280</pmid><doi>10.1111/j.1442-9071.2010.02252.x</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7916-2640</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1442-6404 |
| ispartof | Clinical & experimental ophthalmology, 2010-05, Vol.38 (4), p.346-352 |
| issn | 1442-6404 2155-9570 1442-9071 2155-9570 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_787040003 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Alkalies - adverse effects angiogenesis inhibitor Angiogenesis Inhibitors - administration & dosage Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Bevacizumab Blood Vessels - pathology Burns, Chemical - complications Burns, Chemical - pathology Burns, Chemical - prevention & control Cicatrix - etiology Conjunctiva Cornea - blood supply Cornea - pathology corneal neovascularization Corneal Opacity - etiology Dexamethasone - administration & dosage Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Eye Burns - etiology Eye Burns - pathology Eye Burns - prevention & control Glucocorticoids - administration & dosage Human health and pathology Injections, Intraocular Life Sciences Male Neovascularization, Pathologic - etiology Neovascularization, Pathologic - prevention & control Rats Rats, Inbred BN Sensory Organs steroids Treatment Outcome |
| title | Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A12%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20corneal%20neovascularization%20after%20alkali%20burn:%20comparison%20of%20different%20doses%20of%20bevacizumab%20in%20monotherapy%20or%20associated%20with%20dexamethasone&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Hoffart,%20Louis&rft.date=2010-05&rft.volume=38&rft.issue=4&rft.spage=346&rft.epage=352&rft.pages=346-352&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1111/j.1442-9071.2010.02252.x&rft_dat=%3Cproquest_hal_p%3E787040003%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=787040003&rft_id=info:pmid/21077280&rfr_iscdi=true |